- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | CVRx informiert zum Weltherztag am 29. September / Bluthochdruck: Den wichtigsten Risikofaktor für Herz-Kreislauf-Erkrankungen früh erkennen und behandeln | 318 | news aktuell | Minneapolis (ots) - Herz-Kreislauf-Erkrankungen sind die häufigste Todesursache in Deutschland und weltweit. Viele Risikofaktoren wie Bluthochdruck, erhöhte Cholesterinwerte oder Diabetes entwickeln... ► Artikel lesen | |
| 25.08. | CVRx has an activist investor urging it to get acquired | 3 | MassDevice | ||
| 25.08. | CVRx responds to shareholder letter on company valuation | 2 | Investing.com | ||
| 24.08. | CVRx earns new Medicare Advantage coverage policy for Barostim | 1 | MassDevice | ||
| 24.08. | CVRx, Inc.: CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy | 1 | GlobeNewswire (USA) | ||
| 17.08. | Cantor cuts CVRx stock price target on sales execution challenges | 1 | Investing.com | ||
| 11.08. | CVRx auf der Canaccord Genuity Wachstumskonferenz: Fortschritte bei Kostenerstattung, aber Belastungen im Vertrieb | 1 | Investing.com Deutsch | ||
| CVRX Aktie jetzt für 0€ handeln | |||||
| 11.08. | CVRx to replace CRO after cutting guidance and DOJ civil inquiry | 1 | MassDevice | ||
| 11.08. | CVRx, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | CVRx forecasts 2026 revenue of $58M-$60M amid sales productivity and medicare advantage headwinds | 1 | Seeking Alpha | ||
| 07.08. | Piper Sandler stuft CVRx-Aktie wegen Vertriebs- und Kostenerstattungsproblemen herab | 1 | Investing.com Deutsch | ||
| 07.08. | Piper Sandler cuts CVRx stock rating on sales, reimbursement issues | 2 | Investing.com | ||
| 07.08. | CVRx Stock Is Falling Overnight: Here's What's Driving the Move | 1 | Benzinga.com | ||
| 07.08. | CVRx GAAP EPS of -$0.53 misses by $0.01, revenue of $15.71M beats by $0.16M | 1 | Seeking Alpha | ||
| 06.08. | CVRx, Inc.: CVRx Reports Second Quarter 2026 Financial and Operating Results | 315 | GlobeNewswire (Europe) | MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation... ► Artikel lesen | |
| 29.06. | CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last? | 1 | Zacks | ||
| 09.06. | CVRx CFO Oasheim To Step Down | 1 | RTTNews | ||
| 09.06. | CVRx CFO Jared Oasheim to step down | 1 | Seeking Alpha | ||
| 09.06. | CVRx, Inc.: CVRx Announces Chief Financial Officer Transition | 326 | GlobeNewswire (Europe) | MINNEAPOLIS, June 09, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation... ► Artikel lesen | |
| 03.06. | CVRx, Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,466 | -0,26 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| SERNOVA BIOTHERAPEUTICS | 0,069 | +7,12 % | Dr. Steven S. Sangha: Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc. | Toronto, Ontario--(Newsfile Corp. - September 11, 2026) - Steven Sangha announces he has entered into a voting and support agreement ("Voting Agreement") with Seraxis Holdings, Inc. ("Seraxis") in connection... ► Artikel lesen | |
| CERENOME | 1,658 | -4,93 % | Cerenome, Inc.: Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division | HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announces the appointment of Samantha... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,060 | +5,10 % | ATOSSA THERAPEUTICS, INC. - 8-K, Current Report | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Historischer Wendepunkt - darum fliegt die Aktie! | Volltreffer: Bereits im Frühjahr hatte ich die positive Entwicklung bei Sonoma Pharmaceuticals antizipiert und die Nano-Cap-Aktie als hochinteressante Turnaround-Spekulation vorgestellt. Damals hatte... ► Artikel lesen | |
| TANDEM DIABETES | 14,900 | +1,36 % | Tandem Diabetes Care, Inc.: Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets | Compatibility now available in five countries, with additional markets expected throughout 2026.Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,010 | +4,12 % | Co-Diagnostics, Inc. - 8-K, Current Report | ||
| QUIDELORTHO | 9,076 | -1,99 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,445 | +2,09 % | Veru Inc.: Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress | -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients - -- Phase 2b PLATEAU clinical trial interim analysis and... ► Artikel lesen | |
| LIFEWARD | 7,160 | +1,85 % | Lifeward legt Termin für jährliche und außerordentliche Hauptversammlung 2026 fest | ||
| CLOVER HEALTH INVESTMENTS | 3,940 | +1,55 % | Clover Health Investments, Corp.: Clover Health Announces Departure of Chief Financial Officer and Appointment of Interim Chief Financial Officer; Reiterates Most Recently Issued Financial Guidance for Full Fiscal Year 2026 | WILMINGTON, Del., April 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover" or the "Company"), a physician enablement company committed to bringing access to great... ► Artikel lesen | |
| SENSEONICS | 8,200 | -1,80 % | Senseonics sees activist investor take a major stake | ||
| TEMPEST THERAPEUTICS | 0,780 | -19,14 % | Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform | -Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year -Lead BCMA/GPRC5D dual-targeting in... ► Artikel lesen | |
| NANO-X IMAGING | 0,740 | -0,72 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| IMUNON | 1,220 | 0,00 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |
CVRX INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,955 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CVRX INC finden Sie auf Wallstreet Online.